CpG Methylation Inhibits Prolidase Promoter Driven Transcription

Abstract

Prolidase, a cytosolic exopeptidase, and a member of the matrix metalloproteinase (MMP) family, is encoded by the PEPD gene in humans. Since Prolidase is the only enzyme which can cleave dipeptides containing C‐terminal proline, or hydroxyproline, it plays an essential role in protein metabolism, collagen turnover, and matrix remodeling. Prolidase is essential in several physiological and pathological processes such as wound healing, inflammation, angiogenesis, cell proliferation, and carcinogenesis. Surprisingly, little is known about the molecular and cellular regulation of PEPD gene expression. In initial studies, we observed a dense CG‐rich portion around the transcription start site, suggesting a possible role of promoter methylation in the transcriptional regulation of PEPD gene. To study the transcriptional regulation of PEPD gene, we cloned and characterized the human PEPD promoter. The PEPD promoter was amplified from the human genome via PCR and inserted into a luciferase reporter construct. As demonstrated in our results, increase in luciferase activity was obtained after transfection of the PEPD luciferase reporter in HEK293T, indicating the successful construction of the luciferase reporter. Next, we performed in vitro methylation of the PEPD promoter using SssI methyltransferase which methylates DNA CpG islands. Methylation was confirmed by BstUI digestion that cleaves at unmethylated CpG dinucleotides but not at methylated CpG. The CpG methylation significantly inhibited PEPD promoter activity in comparison to the unmethylated construct. Taken together, we believe, these results will generate new knowledge on the molecular regulation of prolidase and provide better insight in our understanding of regulation of prolidase expression in various physiological and pathological conditions.Support or Funding InformationSupported by National Institutes of Health (NIH) Grants DA037779 and MD007586 (to Jui Pandhare) and DA024558, DA30896, DA033892, DA021471, AI22960 and MD007586 (to Chandravanu Dash). Ireti Eni‐Aganga is supported by RISE Grant. The work is also supported by the RCMI Grant G12MD007586, the Vanderbilt CTSA Grant UL1RR024975, the Meharry Translational Research Center (MeTRC) CTSA grant (U54 RR026140 from NCRR/NIH, the U54 Grant MD007593 from NIMHD/NIH, and the Tennessee Center for AIDS Research (P30 AI110527).This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.